Compare MasterCard Inc (MA) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? MasterCard Inc trades at $608.25 (market cap $528.44B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: MasterCard Inc is far larger — about 540.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and MasterCard Inc pays a 0.58% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold MasterCard Inc for 135 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| MA | MRVI | |
|---|---|---|
Market Cap | $528.44B | $977.37M |
Volume | 3,240,513 | 2,742,564 |
Sector | Financials | Health |
52-Week High | $604.80 | $9.00 |
52-Week Low | $471.55 | $2.83 |
Typical Hold Time | 135 Days | 0 Days |
Enterprise Value | $541.48B | $1.08B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $604.80, up 1.63% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with 2025 revenue of $32.79B and net income of $14.97B, maintaining impressive profit margins above 45%. Recent earnings beats and institutional buying activity support the positive outlook, while the company continues expanding digital payment infrastructure globally.
Mastercard presents a compelling growth opportunity with 80% analyst buy ratings and a $668.67 consensus price target. Key risks include payment industry disruption from stablecoins and AI-driven competitors. The stock's premium valuation (P/E 33.27) requires sustained execution, but strong cash flow generation and strategic positioning support long-term upside potential.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
